77 related articles for article (PubMed ID: 16541608)
21. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.
Mitsiades N; Poulaki V; Mastorakos G; Tseleni-Balafouta ST; Kotoula V; Koutras DA; Tsokos M
J Clin Endocrinol Metab; 1999 Aug; 84(8):2924-32. PubMed ID: 10443700
[TBL] [Abstract][Full Text] [Related]
22. Pleural effusion and serum soluble fas-ligand levels are elevated in different clinical conditions.
Wang PS; Chen YM; Hsieh YL; Yu CF; Tsai CM; Perng RP
Lung; 2002; 180(1):25-32. PubMed ID: 12105754
[TBL] [Abstract][Full Text] [Related]
23. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
24. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
25. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease.
Saussez S; Glinoer D; Chantrain G; Pattou F; Carnaille B; André S; Gabius HJ; Laurent G
Thyroid; 2008 Jul; 18(7):705-12. PubMed ID: 18630998
[TBL] [Abstract][Full Text] [Related]
26. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis.
Shiota G; Oyama K; Noguchi N; Takano Y; Kitaoka S; Kawasaki H
Res Commun Mol Pathol Pharmacol; 1998 Jul; 101(1):3-12. PubMed ID: 9755839
[TBL] [Abstract][Full Text] [Related]
28. Increased soluble Fas ligand concentration in tuberculous pleural effusion.
Wu SH; Chu JJ; Chiang CD
J Formos Med Assoc; 2001 Jan; 100(1):32-4. PubMed ID: 11265257
[TBL] [Abstract][Full Text] [Related]
29. Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions.
Letsas KP; Frangou-Lazaridis M; Skyrlas A; Tsatsoulis A; Malamou-Mitsi V
Pathol Int; 2005 Nov; 55(11):694-702. PubMed ID: 16271081
[TBL] [Abstract][Full Text] [Related]
30. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
32. Distinct effects of soluble and membrane-bound fas ligand on fibroblast-like synoviocytes from rheumatoid arthritis patients.
Audo R; Calmon-Hamaty F; Papon L; Combe B; Morel J; Hahne M
Arthritis Rheumatol; 2014 Dec; 66(12):3289-99. PubMed ID: 25078097
[TBL] [Abstract][Full Text] [Related]
33. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
34. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
[TBL] [Abstract][Full Text] [Related]
35. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
[TBL] [Abstract][Full Text] [Related]
36. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
[TBL] [Abstract][Full Text] [Related]
37. Presence of membrane and soluble forms of Fas ligand and of matrilysin (MMP-7) activity in normal and abnormal human semen.
Riccioli A; Dal Secco V; De Cesaris P; Starace D; Gandini L; Lenzi A; Dondero F; Padula F; Filippini A; Ziparo E
Hum Reprod; 2005 Oct; 20(10):2814-20. PubMed ID: 15979995
[TBL] [Abstract][Full Text] [Related]
38. Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions.
Myong NH
J Korean Med Sci; 2005 Oct; 20(5):770-6. PubMed ID: 16224150
[TBL] [Abstract][Full Text] [Related]
39. Serum and follicular fluid levels of soluble Fas and soluble Fas ligand in IVF cycles.
Onalan G; Selam B; Onalan R; Ceyhan T; Cincik M; Pabuccu R
Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):85-91. PubMed ID: 16140454
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation.
Laskowska M; Laskowska K; Leszczyńska-Gorzelak B; Oleszczuk J
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):155-9. PubMed ID: 16169656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
